An ethical view of the ranibizumab and bevacizumab controversy [5]

Archives of Ophthalmology

Volumn 126, Issue 2, 2008, Pages 286-

  Packer, Samuel ^a   Jampol, Lee M ^b  

^a Northwell Health   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

COST BENEFIT ANALYSIS; DRUG APPROVAL; ECONOMIC ASPECT; ETHICS; FOOD AND DRUG ADMINISTRATION; HEALTH CARE QUALITY; HUMAN; LETTER; PHYSICIAN; PRIORITY JOURNAL; RETINA MACULA DEGENERATION;

EID: 39049120825     PISSN: 00039950     EISSN: 00039950     Source Type: Journal    
DOI: 10.1001/archophthalmol.2007.41     Document Type: Letter

References (8)

1. Miller JW. Using a drug before the risks and benefits are known from a phase 3 clinical trial: thoughts on compassion. Arch Ophthalmol. 2006;124(7):1029-1031.
2. Narayanan R, Kupperman BD. Uncertain compassion in using a drug before the risks and benefits are known. Arch Ophthalmol. 2006;124(7):1032-1034.
3. Morreim EH. Balancing Act: The New Medical Ethics of Medicine's New Economics. Boston, MA: Kluwer Academic Publishers; 1991.
4. Gebhardt DOE. The influence of the pharmaceutical industry on the offlabel use of its medicines. J Med Ethics. 2002;28(4):277.
5. Wong D, Kyle G. Some ethical considerations for the "off-label" use of drugs such as Avastin. Br J Ophthalmol. 2006;90(10):1218-1219.
6. Rich RM, Rosenfeld PPJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina. 2006;26(5):495-511.
7. Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials. JAMA. 2003;290(7):921-928.
8. National Eye Institute, National Institutes of Health. National Eye Institute statement: National Institutes of Health stimulates the development and testing of new therapies for advanced age-related macular degeneration (AMD). http://www.nei.nih.gov/news/statements/amd_therapy.asp. Accessed March 15, 2007.